Can a withdrawn Eli Lilly drug find second life in radiopharma? Little biotech hands over $5M cash to find out
Three years after Eli Lilly pulled Lartruvo from the market, the soft tissue sarcoma drug is getting a second life.
Little Australia-listed biotech Telix Pharmaceuticals …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.